Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Baxter International Inc Stock Research

BAX

37.35USD-0.39(-1.03%)Market Closed
Watchlist

Market Summary

USD37.35-0.39
Market Closed
-1.03%

BAX Alerts

BAX Stock Price

BAX RSI Chart

BAX Valuation

Market Cap

18.9B

Price/Earnings (Trailing)

-6.62

Price/Sales (Trailing)

1.26

EV/EBITDA

-15.67

Price/Free Cashflow

12.12

BAX Price/Sales (Trailing)

BAX Profitability

EBT Margin

-15.79%

Return on Equity

-41.84%

Return on Assets

-8.7%

Free Cashflow Yield

8.25%

BAX Fundamentals

BAX Revenue

Revenue (TTM)

15.0B

Revenue Y/Y

3.14%

Revenue Q/Q

1.59%

BAX Earnings

Earnings (TTM)

-2.9B

Earnings Y/Y

-155.95%

Earnings Q/Q

-420.45%

Price Action

52 Week Range

37.0557.52
(Low)(High)

Last 7 days

-0.4%

Last 30 days

-8%

Last 90 days

-16.4%

Trailing 12 Months

-29.8%

BAX Financial Health

Current Ratio

1.7

Debt/Equity

2.6

Debt/Cashflow

0.1

BAX Investor Care

Shares Dilution (1Y)

0.40%

Diluted EPS (TTM)

-5.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for BAX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-01
Borzi James W
acquired
-
-
12,016
evp, chief supply chain office
2023-09-01
Sonig Alok
sold (taxes)
-83,595
40.6
-2,059
evp, group president, pharm
2023-08-21
RUSCKOWSKI STEPHEN H
acquired
-
-
3,049
-
2023-06-29
Ampofo William A. II
acquired
-
-
3,811
-
2023-06-01
Toth Christopher A.
acquired
-
-
106,358
evp, group pres, kidney care
2023-06-01
Rosenbloom David S.
sold (taxes)
-31,417
41.23
-762
svp and general counsel
2023-06-01
Stevens Brian
acquired
-
-
5,909
svp,interim cfo,cao&cntrl
2023-05-02
Smith Cathy R
acquired
-
-
4,573
-
2023-05-02
Wilkes David S.
acquired
-
-
4,573
-
2023-05-02
Oesterle Stephen N.
acquired
-
-
4,573
-

1–10 of 50

Which funds bought or sold BAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
new
-
6,192,290
6,192,290
0.02%
2023-09-21
Baystate Wealth Management LLC
reduced
-68.27
-39,016
21,621
-%
2023-09-20
BARCLAYS PLC
reduced
-10.6
157,000
38,366,000
0.02%
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-0.93
73,916
728,960
0.30%
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
added
19.88
397,069
1,542,890
1.31%
2023-09-12
Farther Finance Advisors, LLC
added
28.52
16,593
53,989
0.01%
2023-09-12
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
sold off
-100
-16,224,000
-
-%
2023-09-01
Portside Wealth Group, LLC
new
-
781,568
781,568
0.14%
2023-08-29
Garde Capital, Inc.
reduced
-5.36
7,000
108,000
0.01%
2023-08-28
DT Investment Partners, LLC
unchanged
-
-141
2,655
-%

1–10 of 48

Latest Funds Activity

Are funds buying BAX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BAX
No. of Funds

Schedule 13G FIlings of Baxter International

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 09, 2023
morgan stanley
0.6%
3,186,104
SC 13G/A
Apr 10, 2023
wellington management group llp
0.11%
559,390
SC 13G/A
Apr 10, 2023
vanguard group inc
12.03%
60,794,820
SC 13G/A
Feb 09, 2023
vanguard group inc
9.86%
49,705,350
SC 13G/A
Feb 08, 2023
morgan stanley
5.5%
27,835,167
SC 13G/A
Feb 06, 2023
wellington management group llp
7.16%
36,104,233
SC 13G/A
Jan 06, 2023
blackrock inc.
10.0%
50,522,292
SC 13G/A
Mar 10, 2022
wellington management group llp
11.33%
56,894,500
SC 13G/A
Feb 09, 2022
morgan stanley
5.7%
28,501,661
SC 13G
Feb 09, 2022
vanguard group inc
7.79%
38,980,284
SC 13G/A

Recent SEC filings of Baxter International

View All Filings
Date Filed Form Type Document
Oct 02, 2023
8-K
Current Report
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Aug 23, 2023
4
Insider Trading
Aug 23, 2023
3
Insider Trading
Aug 21, 2023
8-K
Current Report
Jul 27, 2023
8-K
Current Report
Jul 27, 2023
10-Q
Quarterly Report
Jul 06, 2023
8-K
Current Report
Jul 03, 2023
4
Insider Trading

Peers (Alternatives to Baxter International)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.0B
19.5B
-3.73% 35.20%
38.38
5.34
10.36% 30.30%
103.6B
6.7B
-4.97% 57.37%
72.72
15.55
11.75% -0.66%
76.4B
13.4B
-1.51% 36.35%
83.74
5.7
8.69% 3.17%
71.3B
19.0B
-7.43% 16.56%
44.09
3.79
0.46% -5.24%
42.1B
5.7B
-9.43% -16.28%
30.27
7.43
5.64% -4.53%
MID-CAP
9.1B
937.8M
-9.65% 25.86%
313.94
9.75
16.30% 250.21%
7.2B
616.6M
-11.74% -29.40%
29.51
11.67
69.52% 343.68%
5.0B
1.1B
-8.56% -16.75%
23.67
4.54
12.63% 50.85%
2.8B
452.1M
-10.08% -26.48%
-28.35
6.22
24.99% 24.09%
1.4B
790.3M
-21.04% -54.04%
-6.37
1.81
3.21% -1604.53%
SMALL-CAP
1.5B
421.8M
-22.58% 43.94%
-9.18
3.63
44.49% -2.43%
945.1M
780.7M
-5.83% -7.35%
-26.25
1.21
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
589.9M
162.9M
-22.80% -66.22%
-11.16
3.62
42.67% 12.82%

Baxter International News

MarketWatch
Baxter International Inc. stock underperforms Monday when compared to competitors.
MarketWatch,
7 hours ago
Morningstar
Zacks Investment Research

Returns for BAX

Cumulative Returns on BAX

2.1%


10-Year Cumulative Returns

-2.2%


7-Year Cumulative Returns

-12.1%


5-Year Cumulative Returns

-20.9%


3-Year Cumulative Returns

Risks for BAX

What is the probability of a big loss on BAX?

43.9%


Probability that Baxter International stock will be more than 20% underwater in next one year

24.2%


Probability that Baxter International stock will be more than 30% underwater in next one year.

14.2%


Probability that Baxter International stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BAX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Baxter International was unfortunately bought at previous high price.

Drawdowns

Financials for Baxter International

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue0.8%15,01614,90315,11314,58814,04113,54512,78412,45112,19711,81711,67311,53111,41011,52611,36211,15611,06611,04511,09911,04010,986
Gross Profit-4.9%5,0545,3145,3975,2585,4465,3085,1054,8904,7644,5694,5874,6944,7294,8444,7614,6464,6484,7184,7594,7404,638
  S&GA Expenses-0.2%3,8333,8393,8873,8543,5873,2922,8672,6322,5532,4682,4692,4852,5112,5622,5352,4962,5532,5882,6202,7462,742
  R&D Expenses2.7%636619605588565556534531525503521542563612595614636642654662646
EBITDA100.0%--1,462-1,345-1,3322,0112,0302,1752,1062,0841,9591,9811,5621,6401,6841,6882,301-----
EBITDA Margin100.0%--0.10*-0.09*-0.09*0.14*0.15*0.17*0.17*0.17*0.17*0.17*0.14*0.14*0.15*0.15*0.21*-----
Interest Expenses-8.2%-462-427-395-352-298-243-192-156-145-147-134-116-90.00-74.00-71.00-62.00-60.00-51.00-45.00-48.00-51.00
Earnings Before Taxes-16.4%-2,855-2,453-2,353-2,3701,0471,2201,4771,4041,3681,2651,2928599259629701,6061,4971,5751,6171,3801,298
EBT Margin100.0%--0.16*-0.16*-0.16*0.08*0.09*0.12*0.11*0.11*0.11*0.11*0.07*0.08*0.08*0.09*0.14*-----
Net Income-16.0%-2,853-2,460-2,433-2,3761,0111,0571,2841,2141,1201,0681,1029119249911,0011,3291,4781,5061,5461,170903
Net Income Margin100.0%--0.16*-0.16*-0.16*0.07*0.08*0.10*0.10*0.09*0.09*0.09*0.08*0.08*0.09*0.09*0.12*-----
Free Cashflow-100.0%-1,4821,2111,4651,8502,0532,2222,2412,0761,9731,8681,9852,1762,2342,1042,030-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-1.4%27,88528,29128,28727,96531,83132,71633,52119,80719,68219,46620,01920,09819,46519,07518,19317,29917,50316,24115,72016,80316,519
  Current Assets1.3%8,2058,0998,0117,8107,8828,1738,8728,1678,0047,8568,4119,0338,5668,3337,5037,2107,2296,0605,9597,0316,884
    Cash Equivalents2.8%1,7201,6731,7181,6011,8522,2942,9563,2583,1363,1823,7304,3594,0854,1103,3353,0002,9341,9021,8382,8632,858
  Inventory-0.9%2,8972,9222,6792,6752,6632,5482,4532,0252,0652,0171,9161,9881,9051,6941,6531,7151,7561,7431,6671,7161,616
  Net PPE-10.1%4,4945,0004,6954,7994,9765,1145,1784,5824,6494,6144,7224,4604,3824,3404,5124,4064,4854,4764,5304,4764,486
  Goodwill-6.6%6,4186,8686,4526,6399,6449,8169,8363,0983,1481.003,2173,0943,0522,9613,0302,8472,9372,9293,002--
Liabilities-0.4%22,25422,35022,39222,38622,92823,59724,40010,99211,14710,97611,29311,49611,30511,34510,2819,6829,7008,6487,8547,7137,689
  Current Liabilities21.1%5,7654,7604,7453,7083,9163,8904,2363,4413,3443,1873,3333,4222,8803,0363,2302,6112,5573,2762,8142,6632,586
  Short Term Borrowings398.0%24950.0029927520020030130151.00---1.00221226-2.007962.00--
  Long Term Debt-6.4%14,30615,27815,23216,153--17,149-------4,809-5,1573,4513,4813,4803,491
Shareholder's Equity-6.3%5,5695,9415,8335,5358,9039,1199,1218,8158,5358,4908,7268,6028,1607,7307,9127,6177,8037,5937,8669,0908,830
  Retained Earnings-2.1%13,65513,94714,05014,01517,09916,99417,06516,96716,65816,50216,32816,28516,05515,93515,71815,84915,59815,41415,07514,88614,484
  Additional Paid-In Capital0.5%6,3416,3126,3226,2976,2536,2076,1976,1316,0906,0436,0436,0095,9755,9355,9555,9265,9065,8395,8985,9315,916
Shares Outstanding0.2%506505-504504503-500503505-511509507-511510512-534535
Minority Interest0%62.0062.0062.0044.0044.0044.0044.0045.0041.0038.0037.0035.0032.0031.0030.0029.0024.0023.0022.00-17.00-12.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations5.2%1,5591,4821,2111,4651,8502,0532,2222,2412,0761,9731,8681,9852,1762,2482,1041,9841,7591,7152,0171,6991,828
  Share Based Compensation-5.4%139147154175164156146126125123130127129129122120118117115117115
Cashflow From Investing1.8%-783-797-931-10,942-10,965-10,966-11,200-1,197-1,147-1,113-1,179-1,336-1,410-1,403-1,100-895-833-846-916-904-1,510
Cashflow From Financing27.7%-913-1,262-1,4387,9577,9358,0558,245-2,174-1,961-1,873-3456824391,430498-894-827-1,820-2,603-1,393-1,281
  Dividend Payments0.9%584579573567562545530515499487473461448433423412401390376361347
  Buy Backs---32.0032.0035.003476001,1001,0657535002415506731,2702,4532,3912,5272,4521,3171,250

BAX Income Statement

2023-06-30
Condensed Consolidated Statements of Income (Loss) (unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Net sales$ 3,707$ 3,594$ 7,220$ 7,152
Cost of sales2,5962,2234,8344,519
Gross margin1,1111,3712,3862,633
Selling, general and administrative expenses9649701,9592,017
Research and development expenses165148329297
Other operating income, net(1)(11)(14)(28)
Operating income (loss)(17)264112347
Interest expense, net12489241174
Other (income) expense, net42(44)40(60)
Income (loss) from continuing operations before income taxes(183)219(169)233
Income tax expense10342440
Income (loss) from continuing operations(193)185(193)193
Income from discontinued operations, net of tax547099135
Net income (loss)(139)255(94)328
Net income attributable to noncontrolling interests2335
Net income (loss) attributable to Baxter stockholders$ (141)$ 252$ (97)$ 323
Income (loss) from continuing operations per common share    
Income from continuing operations per common share, basic (in dollars per share)$ (0.39)$ 0.36$ (0.39)$ 0.37
Income from continuing operations per common share, diluted (in dollars per share)(0.39)0.36(0.39)0.37
Income from discontinued operations per common share    
Income from discontinued operations per common share, basic (in dollars per share)0.110.140.200.27
Income from discontinued operations per common share, diluted (in dollars per share)0.110.140.200.27
Net income (loss) per common share    
Basic (in dollars per share)(0.28)0.50(0.19)0.64
Diluted (in dollars per share)$ (0.28)$ 0.50$ (0.19)$ 0.64
Weighted-average number of shares outstanding    
Basic (in shares)506504506503
Diluted (in shares)506508506508

BAX Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,722$ 1,718
Accounts receivable, net of allowances of $128 in 2023 and $114 in 20222,4952,571
Inventories2,8972,679
Prepaid expenses and other current assets858857
Current assets of discontinued operations233186
Total current assets8,2058,011
Property, plant and equipment, net4,4944,695
Goodwill6,4186,452
Other intangible assets, net6,4706,793
Operating lease right-of-use assets533541
Other non-current assets1,0671,109
Non-current assets of discontinued operations698686
Total assets27,88528,287
Current liabilities:  
Short-term debt249299
Current maturities of long-term debt and finance lease obligations1,9281,105
Accounts payable1,2401,110
Accrued expenses and other current liabilities2,2782,170
Current liabilities of discontinued operations7061
Total current liabilities5,7654,745
Long-term debt and finance lease obligations, less current portion14,30615,232
Operating lease liabilities438447
Other non-current liabilities1,6221,848
Non-current liabilities of discontinued operations123120
Total liabilities22,25422,392
Commitments and contingencies
Equity:  
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2023 and 2022683683
Common stock in treasury, at cost, 177,125,182 shares in 2023 and 179,062,594 shares in 2022(11,296)(11,389)
Additional contributed capital6,3416,322
Retained earnings13,65514,050
Accumulated other comprehensive income (loss)(3,814)(3,833)
Total Baxter stockholders’ equity5,5695,833
Noncontrolling interests6262
Total equity5,6315,895
Total liabilities and equity$ 27,885$ 28,287
José E. Almeida
60000
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.